185-POS

Abstract

Objectives (1) To collect both retrospective and prospective study cohorts of pregnant women with clinical data and biological material (blood, urine, placenta) from variety of pregnancy complications (pregnancy loss, preeclampsia, gestational diabetes, fetal growth disorders) for development of new biomarkers. (2) To translate the discovery findings from retrospective study cohort containing the selected and well-characterized clinical phenotypes into clinical practice using longitudinal sample collection. Methods REPROMETA (REPROgrammed fetal and/or maternal METAbolism) study individuals (family trios/duos) were recruited at delivery at the Women Clinic of Tartu University Hospital in 2006–2011. The babies were followed-up for two years. In the frame of the ongoing prospective study HAPPY PREGNANCY (“Development of novel non-invasive biomarkers for fertility and healthy pregnancy”; 2013–2015) we are collecting longitudinal anthropometric, epidemiological, clinical data and biological material thorough the pregnancy and at delivery. The estimated number of participants is 2500. Results Retrospective sample collection consists of 366 families: (1) uncomplicated pregnancy resulted with term delivery of baby with normal birth weight ( n = 110); (2) babies of large ( n = 89); and (3) small for gestational age ( n = 64); (4) cases of severe preeclampsia ( n = 50); (5) gestational diabetes ( n = 53). None of the children had genetic syndrome or late-onset of congenital malfunction at the age of 2 years. The biological material (DNA, RNA, plasma, paraffin blocks) have used in several studies (Mannik et al., 2010, 2012; Uuskula et al., 2012). The quality of the samples was featured in an editorial of JCEM (Freemark, 2010). The HAPPY PREGNANCY study is recruiting 2/3 of all pregnant women visiting Women’s Hospital. Preliminary prevalence of preeclampsia is 3.8%, preterm delivery 5.4%, multiple pregnancy 5.4%, gestational diabetes 4.1% in study cohort ( www.happypregnancy.ut.ee/eng ). Conclusions We have been creating a powerful biobank enabling development of new biomarkers from discovery to clinical practice. FUNDING: European Regional Development Fund (project 3.2.0701.12-0047). Disclosures K. Rull: None. P. Vaas: None. E. Hanson: None. P. Teesalu: None. T. Rebane: None. M. Laan: None.